Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract

[[abstract]]Both gemcitabine and weekly 24-h infusion of high-dose 5-fluorouracil/leucovorin (HDFL) have shown promising antitumour activity for patients with locally advanced or metastatic carcinoma of the biliary tract (CBT). From April 1999 through December 2002, 30 patients with inoperable CBT were treated with gemcitabine 800 mg m(-2), intravenous infusion for 30 min, followed by 5-FU, 2000 mg m(-2) and leucovorin, 300 mg m(-2), intravenous infusion for 24 h, on day 1, 8 and 15, every 4 weeks. A total of 166 cycles were given (median of four cycles per patient, range 1-24 cycles). Response was evaluable in 28 patients and toxicity in 29 patients. Partial response was obtained in six patients, stable disease in 13, while progressive disease occurred in nine. The objective response rate was 21.4% (95% CI: 5.2-37.6%). The most common grade 3 or 4 toxicity was infection (nine patients). Other types of grade 3 or 4 toxicity included leucopenia (four patients), thrombocytopenia (three patients), anaemia (three patients), nausea/vomiting (two patients) and elevation of liver transaminases (three patients). As of 30 September 2003, the median progression-free survival was 3.7 months (95% CI: 2.8-4.6 months) and the median overall survival was 4.7 months (95% CI: 0.8-8.6 months). Our data suggest that weekly gemcitabine plus HDFL is modestly active with acceptable treatment-related toxicity for patients with advanced CBT

Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer

BACKGROUND: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies and appears to arise mainly from transformation of pre-existing differentiated thyroid cancer (DTC). However, the carcinogenic mechanism of anaplastic transformation remains unclear. Previously, we investigated specific genes related to ATC based on gene expression profiling using cDNA microarray analysis. One of these genes, transcription elongation factor A (SII)-like 4 (TCEAL4), encodes a member of the transcription elongation factor A (SII)-like gene family. The detailed function of TCEAL4 has not been described nor has any association between this gene and human cancers been reported previously. METHODS: To investigate the role of TCEAL4 in ATC carcinogenesis, we examined expression levels of TCEAL4 in ACLs as well as in other types of thyroid cancers and normal human tissue. RESULTS: Expression of TCEAL4 was down-regulated in all 11 ACLs as compared to either normal thyroid tissues or papillary and follicular thyroid cancerous tissues. TCEAL4 was expressed ubiquitously in all normal human tissues tested. CONCLUSION: To our knowledge, this is the first report of altered TCEAL4 expression in human cancers. We suggest that loss of TCEAL4 expression might be associated with development of ATC from DTC. Further functional studies are required

Specific-heat study of superconducting and normal states in FeSe1-xTex (0.6<=x<=1) single crystals: Strong-coupling superconductivity, strong electron-correlation, and inhomogeneity

The electronic specific heat of as-grown and annealed single-crystals of FeSe1-xTex (0.6<=x<=1) has been investigated. It has been found that annealed single-crystals with x=0.6-0.9 exhibit bulk superconductivity with a clear specific-heat jump at the superconducting (SC) transition temperature, Tc. Both 2Delta_0/kBTc [Delta_0: the SC gap at 0 K estimated using the single-band BCS s-wave model] and Delta C/(gamma_n-gamma_0)Tc [Delta C$: the specific-heat jump at Tc, gamma_n: the electronic specific-heat coefficient in the normal state, gamma_0: the residual electronic specific-heat coefficient at 0 K in the SC state] are largest in the well-annealed single-crystal with x=0.7, i.e., 4.29 and 2.76, respectively, indicating that the superconductivity is of the strong coupling. The thermodynamic critical field has also been estimated. gamma_n has been found to be one order of magnitude larger than those estimated from the band calculations and increases with increasing x at x=0.6-0.9, which is surmised to be due to the increase in the electronic effective mass, namely, the enhancement of the electron correlation. It has been found that there remains a finite value of gamma_0 in the SC state even in the well-annealed single-crystals with x=0.8-0.9, suggesting an inhomogeneous electronic state in real space and/or momentum space.Comment: 22 pages, 1 table, 6 figures, Version 2 has been accepted for publication in J. Phys. Soc. Jp

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

[[abstract]]To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid ( FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m(-2) 2-h intravenous infusion, and 5-FU 2600 mg m(-2) plus FA 300 mg m(-2) 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22-75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8-70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-up time of 24.0 months. Major grades 3-4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated

Raman study of carrier-overdoping effects on the gap in high-Tc superconducting cuprates

Raman scattering in the heavily overdoped (Y,Ca)Ba_2Cu_3O_{7-d} (T_c = 65 K) and Bi_2Sr_2CaCu_2O_{8+d} (T_c = 55 K) crystals has been investigated. For the both crystals, the electronic pair-breaking peaks in the A_{1g} and B_{1g} polarizations were largely shifted to the low energies close to a half of 2Delta_0, Delta_0 being the maximum gap. It strongly suggests s-wave mixing into the d-wave superconducting order parameter and the consequent manifestation of the Coulomb screening effect in the B_{1g}-channel. Gradual mixing of s-wave component with overdoping is not due to the change of crystal structure symmetry but a generic feature in all high-T_c superconducting cuprates.Comment: 5 pages, 4 figures, to be published in Phys. Rev. B, Rapid communicaito

Calculation of atomic spontaneous emission rate in 1D finite photonic crystal with defects

We derive the expression for spontaneous emission rate in finite one-dimensional photonic crystal with arbitrary defects using the effective resonator model to describe electromagnetic field distributions in the structure. We obtain explicit formulas for contributions of different types of modes, i.e. radiation, substrate and guided modes. Formal calculations are illustrated with a few numerical examples, which demonstrate that the application of effective resonator model simplifies interpretation of results.Comment: Cent. Eur. J. Phys, in pres

An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer

The aim of the study was to evaluate the response rate and safety of weekly paclitaxel (Taxol®) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1 : 4 molar ratio) and leucovorin (LV) in patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-h infusion at a dose of 100 mg m−2 on days 1 and 8 and oral UFT 300 mg m−2 day−1 plus LV 90 mg day−1 were given starting from day 1 for 14 days, followed by a 7-day period without treatment. Treatment was repeated every 21 days. From February 2003 to October 2004, 55 patients were enrolled. The median age was 62 years (range: 32–82). Among the 48 patients evaluated for tumour response, two achieved a complete response and 22 a partial response, with an overall response rate of 50% (95% confidence interval: 35–65%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.4 and 9.8 months, respectively. Major grade 3–4 toxicities were neutropenia in 25 patients (45%) and diarrhoea in eight patients (15%). Although treatment was discontinued owing to treatment-related toxicities in nine patients (16%), there was no treatment-related mortality. Weekly paclitaxel plus oral UFT/LV is effective, convenient, and well tolerated in treating patients with advanced gastric cancer

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer

We prospectively investigated the efficacy and safety of combining weekly vinorelbine (VNB) with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in the treatment of patients with advanced breast cancer (ABC). Vinorelbine 25 mg m−2 30-min intravenous infusion, and high-dose 5-FU 2600 mg m−2 plus LV 300 mg m−2 24-h intravenous infusion (HDFL regimen) were given on days 1 and 8 every 3 weeks. Between June 1999 and April 2003, 40 patients with histologically confirmed recurrent or metastatic breast cancer were enrolled with a median age of 49 years (range: 36–68). A total of 25 patients had recurrent ABC, and 15 patients had primary metastatic diseases. The overall response rate for the intent-to-treat group was 70.0% (95% CI: 54–84%) with eight complete responses and 20 partial responses. All 40 patients were evaluated for survival and toxicities. Among a total of 316 cycles of VNB–HDFL given (average: 7.9: range: 4–14 cycles per patient), the main toxicity was Gr3/4 leucopenia and Gr3/4 neutropenia in 57 (18.0%) and 120 (38.0%) cycles, respectively. Gr1/2 infection and Gr1/2 stomatitis were noted in five (1.6%) and 59 (18.7%) cycles, respectively. None of the patients developed Gr3/4 stomatitis or Gr3/4 infection. Gr2/3 and Gr1 hand–foot syndrome was noted in two (5.0%) and 23 (57.5%) patients, respectively. Gr1 sensory neuropathy developed in three patients. The median time to progression was 8.0 months (range: 3–25.5 months), and the median overall survival was 25.0 months with a follow-up of 5.5 to 45+ months. This VNB–HDFL regimen is a highly active yet well-tolerated first-line treatment for ABC

Physical properties of FeSe0.5_{0.5}Te0.5_{0.5} single crystals grown under different conditions

We report on structural, magnetic, conductivity, and thermodynamic studies of FeSe$_{0.5}$Te$_{0.5}$ single crystals grown by self-flux and Bridgman methods. The samples were prepared from starting materials of different purity at various temperatures and cooling rates. The lowest values of the susceptibility in the normal state, the highest transition temperature $T_c$ of 14.5 K, and the largest heat-capacity anomaly at $T_c$ were obtained for pure (oxygen-free) samples. The critical current density $j_c$ of $8 \times 10^4$ A/cm$^2$ (at 2 K) achieved in pure samples is attributed to intrinsic inhomogeneity due to disorder at the cation and anion sites. The impure samples show increased $j_c$ up to $2.3 \times 10^5$ A/cm$^2$ due to additional pinning centers of Fe$_3$O$_4$. The upper critical field $H_{c2}$ of $\sim 500$ kOe is estimated from the resistivity study in magnetic fields parallel to the \emph{c}-axis. The anisotropy of the upper critical field $\gamma_{H_{c2}} = H_{_{c2}}^{ab}/H_{_{c2}}^{c}$ reaches a value $\sim 6$ at $T\longrightarrow T_c$. Extremely low values of the residual Sommerfeld coefficient for pure samples indicate a high volume fraction of the superconducting phase (up to 97%). The electronic contribution to the specific heat in the superconducting state is well described within a single-band BCS model with a temperature dependent gap $\Delta_0 = 27(1)$ K. A broad cusp-like anomaly in the electronic specific heat of samples with suppressed bulk superconductivity is ascribed to a splitting of the ground state of the interstitial Fe$^{2+}$ ions. This contribution is fully suppressed in the ordered state in samples with bulk superconductivity.Comment: 11 pages, 11 figures, 3 table

Studies of the Decay B+- -> D_CP K+-

We report studies of the decay B+- -> D_CP K+-, where D_CP denotes neutral D mesons that decay to CP eigenstates. The analysis is based on a 29.1/fb data sample of collected at the \Upsilon(4S) resonance with the Belle detector at the KEKB asymmetric e+ e- storage ring. Ratios of branching fractions of Cabibbo-suppressed to Cabibbo-favored processes involving D_CP are determined to be B(B- -> D_1 K-)/B(B- -> D_1 pi-)=0.125 +- 0.036 +- 0.010 and B(B- -> D_2 K-)/B(B- -> D_2 pi-)=0.119 +- 0.028 +- 0.006, where indices 1 and 2 represent the CP=+1 and CP=-1 eigenstates of the D0 - anti D0 system, respectively. We also extract the partial rate asymmetries for B+- -> D_CP K+-, finding A_1 = 0.29 +- 0.26 +- 0.05 and A_2 = -0.22 +- 0.24 +- 0.04.Comment: 10 pages, 2 figures, submitted to Physical Review Letter